$56.57
3.78% yesterday
Nasdaq, Sep 17, 10:00 pm CET
ISIN
US7207951036
Symbol
PVLA

Pieris Pharmaceuticals, Inc. Stock price

$56.57
+7.02 14.17% 1M
+29.07 105.71% 6M
+44.57 371.42% YTD
+40.01 241.61% 1Y
-47.43 45.61% 3Y
-182.63 76.35% 5Y
-150.63 72.70% 10Y
-163.43 74.29% 20Y
Nasdaq, Closing price Wed, Sep 17 2025
+2.06 3.78%
ISIN
US7207951036
Symbol
PVLA
Industry

Key metrics

Basic
Market capitalization
$625.7m
Enterprise Value
$555.2m
Net debt
positive
Cash
$70.4m
Shares outstanding
11.1m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
13.1
Financial Health
Equity Ratio
71.0%
Return on Equity
-27.2%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-33.9m
EBIT
- | $-37.3m
Net Income
- | $-35.3m
Free Cash Flow
$-14.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -166.1%
Net Income
- | -107.5%
Free Cash Flow
61.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.3
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Pieris Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Pieris Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Pieris Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.65 3.65
78% 78%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
21% 21%
-
Net Profit -22 -22
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pieris Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pieris Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 22 hours ago
Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systematic review of 26 studies evaluating the use of rapamycin for the treatment of venous malformations Study authors highlight unmet clinical need for ...
Neutral
GlobeNewsWire
3 days ago
Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025
Neutral
GlobeNewsWire
15 days ago
Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies
More Pieris Pharmaceuticals, Inc. News

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Head office United States
CEO Wesley Kaupinen
Founded 2001
Website palvellatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today